Posts Tagged ‘tirzepatide’

The Unfortunate Gray Market for Obesity Medicines

July 22, 2024 — A gray market for obesity medicines is thriving. The quality of the products in this market range from reasonable to sketchy to utterly unreliable. But millions of people are taking a chance on them. Big pharma companies innovated to bring fully vetted formulations of important medicines to market, spending billions of dollars to do it. […]

A Sketchy Head-to-Head Study of Tirzepatide and Semaglutide

July 10, 2024 — The headline is compelling. “Zepbound outperforms Ozempic and Wegovy in head-to-head weight loss study.” It certainly confirms the bias of a lot of people in the field. But is it true? Did tirzepatide (Zepbound) really beat semaglutide (Wegovy) in a head-to-head comparative study for obesity? In a word, no. Uncontrolled, Observational, and Inequivalent Dosing The […]

Semaglutide at ADA2024: Old News or Gaining Momentum?

June 25, 2024 — It’s over. The 84th Scientific Sessions of the American Diabetes Association came to an end yesterday and for anyone interested in obesity, it has given us a lot to absorb. After four days with a steady stream of new information about drugs like the GLP-1 agonists that regulate appetite and adiposity, we are left wondering. […]

A First and a Burst of Evidence for Sleep Apnea and Obesity

June 22, 2024 — We like to celebrate firsts. And yesterday, we got one to celebrate in the first ever drug treatment shown to be effective for sleep apnea – the obesity medicine called tirzepatide. In presenting this new research at the American Diabetes Association Scientific Sessions yesterday, Atul Malhotra reminded us, “sleep is an important part of cardiometabolic […]

Survodutide and Tirzepatide Dash for a Splash with MASH

June 9, 2024 — At the EASL Congress 2024 in Milan, we witnessed quite a splash of new data on both survodutide and tirzepatide for MASH. Friday and Saturday gave us two headline presentations at the meeting and two publications in the New England Journal of Medicine. Lilly pronounced itself “very pleased” with the results of their SYNERGY-NASH study […]

A Little More Detail on Tirzepatide in MASH at EASL

June 6, 2024 — On the opening day of the EASL Congress in Milan, we got a peek at more details on the results of the phase 2 study of tirzepatide in MASH (metabolic dysfunction associated steatohepatitis). The study, called SYNERGY-NASH, will be the subject of a late-breaking presentation on Saturday at the meeting. But the release of the […]

Compounded Obesity Medicines Signal Distress

June 1, 2024 — This is a problem of human mistakes. Compounding pharmacies are exploiting the failure of pharmaceutical companies to meet the scale of need for effective obesity medicines. So people with a serious medical need for these medicines face a hideous choice. Suffer without them or take a chance on dodgy compounded products. The fact that this […]

Pressure Builds on GLP-1 Pricing, with More to Come

April 30, 2024 — Last week, the U.S. Senate launched an investigation into the high price of semaglutide, sold as Ozempic and Wegovy by Novo Nordisk. Yes, pressure on GLP-1 pricing is building and you can be confident there’s more to come. Senator Bernie Sanders chairs the Senate Committee on Health, Education, Labor, and Pensions, which is undertaking this […]

Two New Studies Suggest a Sleep Apnea Benefit for Tirzepatide

April 18, 2024 — Yesterday, Eli Lilly and Company announced topline results for two studies of tirzepatide in people with obesity and sleep apnea. Both in people who were using CPAP devices and in those who were not, the year-long studies yielded results that independent sleep medicine researchers described as “awesome” and “phenomenal.” Clinical scientists will present the details […]

How Often Does Metabolic Surgery Cure Sleep Apnea?

April 6, 2024 — Sleep apnea is a complication of obesity and at the same time, obesity can be a complication of sleep apnea. This two-way relationship sets up a problem that is serious and can be hard to resolve. But it deserves close attention because it can lead to an early death. So, given the tangled relationship between […]